Response Biomedical's Q2 Revenues Slide 18 Percent
August 10, 2010
Response Biomedical's Q2 Revenues Slide 18 Percent
While product revenues improved, driven by double-digit growth in clinical products, the company took a 79 percent hit in its contract service fees and revenues from collaborative research arrangements.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.